Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
70.7M
-
Shares change
-
-576K
-
Total reported value, excl. options
-
$1.23B
-
Value change
-
-$9.09M
-
Put/Call ratio
-
1.27
-
Number of buys
-
40
-
Number of sells
-
-50
-
Price
-
$17.42
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2019
124 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2019.
Denali Therapeutics Inc. - Common Stock (DNLI) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.7M shares
of 145M outstanding shares and own 48.69% of the company stock.
Largest 10 shareholders include Crestline Management, LP (19.5M shares), Flagship Pioneering Inc. (7.98M shares), BAILLIE GIFFORD & CO (7.59M shares), VANGUARD GROUP INC (6.21M shares), BlackRock Inc. (5.25M shares), Temasek Holdings (Private) Ltd (4.41M shares), FMR LLC (4.12M shares), STATE STREET CORP (1.6M shares), Casdin Capital, LLC (1.25M shares), and WASATCH ADVISORS INC (1.06M shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.